keyword
MENU ▼
Read by QxMD icon Read
search

arb cancer

keyword
https://www.readbyqxmd.com/read/28192226/use-of-preventive-medication-in-patients-with-limited-life-expectancy-a-systematic-review
#1
REVIEW
Arjun Poudel, Patsy Yates, Debra Rowett, Lisa M Nissen
CONTEXT: Optimal prescribing in patients with limited life expectancy (LLE) remains unclear. OBJECTIVES: This study systematically reviews the published literature regarding the use of preventive medication in patients with reduced life expectancy. METHODS: A systematic literature search was conducted using three databases (MEDLINE, EMBASE, and CINAHL). Articles published in English from January 1995 to December 2015 were retrieved for analysis to identify peer-reviewed, observational studies assessing use of preventive medications in patients with LLE...
February 9, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28131779/relationship-between-drugs-affecting-the-renin-angiotensin-system-and-colorectal-cancer-the-mcc-spain-study
#2
Trinidad Dierssen-Sotos, Inés Gómez-Acebo, Camilo Palazuelos, Francisco Rodriguez-Moranta, Beatriz Pérez-Gómez, José Pedro Fernández Vazquez, Pilar Amiano, Aurelio Barricarte, Benito Mirón-Pozo, Adonina Tardon, Rocío Capelo, Rosana Peiro Pérez, José María Huerta, Montserrat Andreu, Mª Ángeles Sierra, Carmen Castañón López, Irune Ruiz, Concepción Moreno-Iribas, Rocío Olmedo-Requena, Gemma Castaño-Vinyals, Nuria Aragonés, Manolis Kogevinas, Marina Pollán, Javier Llorca
The potential protective effect of renin-angiotensin system (RAS) inhibitors is a subject of increasing interest due to their possible role as chemopreventive agents against colorectal cancer (CRC). To evaluate this association, we conducted a case-control study with 2165 cases of colorectal cancer, diagnosed between 2007 and 2012, and 3912 population controls frequency matched (by age, sex and region) from the Spanish multicenter case-control study MCC-Spain. We found a significant protective effect of the angiotensin-converting enzyme Inhibitors (ACEIs) against CRC, limited to the under-65years group (OR=0...
January 26, 2017: Preventive Medicine
https://www.readbyqxmd.com/read/28079518/angiotensin-receptor-blockers-and-the-risk-of-cancer-data-mining-of-a-spontaneous-reporting-database-and-a-claims-database%C3%A2
#3
Mai Fujimoto, Migiwa Kanou, Kouichi Hosomi, Mitsutaka Takada
OBJECTIVE: The aim of this study was to examine the associations between angiotensin receptor blockers (ARBs) and the risk of 10 major cancers by employing different pharmacoepidemiological assessments. MATERIALS AND METHODS: Data from the first quarter of 2004 through 2012 were downloaded from the US Food and Drug Administration Adverse Event Reporting System (FAERS). The reporting odds ratio (ROR) and information component (IC) were used to detect the signals...
January 12, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28055971/src-promotes-castration-recurrent-prostate-cancer-through-androgen-receptor-dependent-canonical-and-non-canonical-transcriptional-signatures
#4
Indranil Chattopadhyay, Jianmin Wang, Maochun Qin, Lingqiu Gao, Renae Holtz, Robert L Vessella, Robert W Leach, Irwin H Gelman
Progression of prostate cancer (PC) to castration-recurrent growth (CRPC) remains dependent on sustained expression and transcriptional activity of the androgen receptor (AR). A major mechanism contributing to CRPC progression is through the direct phosphorylation and activation of AR by Src-family (SFK) and ACK1 tyrosine kinases. However, the AR-dependent transcriptional networks activated by Src during CRPC progression have not been elucidated. Here, we show that activated Src (Src527F) induces androgen-independent growth in human LNCaP cells, concomitant with its ability to induce proliferation/survival genes normally induced by dihydrotestosterone (DHT) in androgen-dependent LNCaP and VCaP cells...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28052030/the-angiotensin-ii-type-1-receptor-antagonist-telmisartan-inhibits-cell-proliferation-and-tumor-growth-of-esophageal-adenocarcinoma-via-the-ampk%C3%AE-mtor-pathway-in-vitro-and-in-vivo
#5
Shintaro Fujihara, Asahiro Morishita, Kana Ogawa, Tomoko Tadokoro, Taiga Chiyo, Kiyohito Kato, Hideki Kobara, Hirohito Mori, Hisakazu Iwama, Tsutomu Masaki
Telmisartan, a widely used antihypertensive drug, is an angiotensin II type 1 (AT1) receptor blocker (ARB). This drug inhibits cancer cell proliferation, but the underlying mechanisms in various cancers, including esophageal cancer, remain unknown. The aim of the present study was to evaluate the effects of telmisartan on human esophageal cancer cell proliferation in vitro and in vivo. We assessed the effects of telmisartan on human esophageal adenocarcinoma (EAC) cells using the cell lines OE19, OE33, and SKGT-4...
January 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28027584/interleukin-6-dependent-genomic-instability-heralds-accelerated-carcinogenesis-following-liver-regeneration-on-a-background-of-chronic-hepatitis
#6
Tali Lanton, Anat Shriki, Yael Nechemia-Arbely, Rinat Abramovitch, Orr Levkovitch, Revital Adar, Nofar Rosenberg, Mor Paldor, Daniel Goldenberg, Amir Sonnenblick, Amnon Peled, Stefan Rose-John, Eithan Galun, Jonathan H Axelrod
Liver cancer, which typically develops on a background of chronic liver inflammation, is now the second leading cause of cancer mortality worldwide. For patients with liver cancer, surgical resection is a principal treatment modality that offers a chance of prolonged survival. However, tumor recurrence after resection, the mechanisms of which remain obscure, markedly limits the long-term survival of these patients. We have shown that partial hepatectomy in multidrug resistance 2 knockout (Mdr2(-/-) ) mice, a model of chronic inflammation-associated liver cancer, significantly accelerates hepatocarcinogenesis...
December 27, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27965461/kras-mutant-colorectal-cancer-gene-signatures-identified-angiotensin-ii-receptor-blockers-as-potential-therapies
#7
Qing Wen, Philip D Dunne, Paul G O'Reilly, Gerald Li, Anthony J Bjourson, Darragh G McArt, Peter W Hamilton, Shu-Dong Zhang
Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC patients.In this study, we employed a novel and comprehensive approach of gene expression connectivity mapping (GECM) to identify candidate compounds to target KRAS-MT tumors...
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/27957711/the-role-of-beta-blockers-in-the-treatment-of-hypertension
#8
John M Cruickshank
IMPORTANCE: Two major guide-line committees (JNC-8 and NICE UK) have dropped beta-blockers as first-line therapy in the treatment of hypertension. Also, recent meta-analyses (that do not take age into account) have concluded that beta-blockers are inappropriate first-line agents in the treatment of hypertension. This review seeks to shed some light on the "rights and wrongs" of such actions and conclusions. OBJECTIVES: Because the pathophysiology of primary/essential hypertension differs in elderly and younger subjects, the latter being closely linked to obesity and increased sympathetic nerve activity, the author sought to clarify the efficacy of beta-blockers in the younger/middle-aged group in reducing the risk of death, and cardiovascular end-points...
December 13, 2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27943160/melanoma-and-non-melanoma-skin-cancer-associated-with-angiotensin-converting-enzyme-inhibitors-angiotensin-receptor-blockers-and-thiazides-a-matched-cohort-study
#9
Beatrice Nardone, Sara Majewski, Ashley S Kim, Tina Kiguradze, Estela M Martinez-Escala, Rivka Friedland, Ahmad Amin, Anne E Laumann, Beatrice J Edwards, Alfred W Rademaker, Mary C Martini, Dennis P West
INTRODUCTION: Controversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), and thiazides (TZs) and the risk of malignant melanoma (MM), and non-melanoma skin cancer-basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). OBJECTIVE: The aim of this study was to determine if an association exists for ACEI, ARB, or TZ exposure and skin cancers. METHODS: This was a matched cohort study using a large electronic medical records repository, the Northwestern Medicine Enterprise Data Warehouse (NMEDW)...
December 9, 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27846200/the-use-of-drugs-acting-on-the-renin-angiotensin-system-and-the-incidence-of-pancreatic-cancer
#10
Victoria Mandilaras, Nathaniel Bouganim, Hui Yin, Jamil Asselah, Laurent Azoulay
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensives. Recently, these drugs have been associated with a protective effect against pancreatic cancer, but data on this putative association remain limited. Thus, the objective of this study was to determine whether the use of ACEIs and/or ARBs is associated with a decreased risk of pancreatic cancer. METHODS: We conducted a population-based cohort study, using a nested case-control analysis within the UK Clinical Practice Research Datalink population...
January 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/27779548/cervix-cancer-research-network-ccrn-improving-access-to-cervix-cancer-trials-on-a-global-scale
#11
David Gaffney, Bill Small, Henry Kitchener, Sang Young Ryu, Akila Viswanathan, Ted Trimble, Al Covens, Sarikapan Wilailak, Arb-Aroon Lertkhachonsuk, Chomporn Sitathanee, Umesh Mahantshetty, Brandon Fisher, Susan Springer, Thomas Pollatz, Antonius Spiller, Monica Bacon, Anuja Jhingran
Eighty-seven percent of cervix cancer occurs in less-developed regions of the world, and there is up to an 18-fold difference in mortality rate for cervix cancer depending on the region of the world. The Cervix Cancer Research Network (CCRN) was founded through the Gynecologic Cancer InterGroup with the aim of improving access to clinical trials in cervix cancer worldwide, and in so doing improving standards of care. The CCRN recently held its first international educational symposium in Bangkok. Sixty-two participants attended from 16 different countries including Pakistan, India, Bangladesh, Thailand, Malaysia, Singapore, Philippines, Taiwan, China, Vietnam, Korea, Japan, Columbia, Brazil, Canada, and the United States...
November 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27641228/global-analysis-of-transcription-in-castration-resistant-prostate-cancer-cells-uncovers-active-enhancers-and-direct-androgen-receptor-targets
#12
Sari Toropainen, Einari A Niskanen, Marjo Malinen, Päivi Sutinen, Minna U Kaikkonen, Jorma J Palvimo
Androgen receptor (AR) is a male sex steroid-activated transcription factor (TF) that plays a critical role in prostate cancers, including castration-resistant prostate cancers (CRPC) that typically express amplified levels of the AR. CRPC-derived VCaP cells display an excessive number of chromatin AR-binding sites (ARBs) most of which localize to distal inter- or intragenic regions. Here, we analyzed direct transcription programs of the AR in VCaP cells using global nuclear run-on sequencing (GRO-seq) and integrated the GRO-seq data with the ARB and VCaP cell-specific TF-binding data...
September 19, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27631721/angiotensin-receptor-blockers-and-breast-cancer-risk-a-meta-analysis
#13
Yun F Qian, Wei G Xu, Jun Wu
INTRODUCTION: Some studies reported that Angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results. EVIDENCE ACQUISITION: The Pubmed and Embase databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI). EVIDENCE SYNTHESIS: Eight eligible literatures with 1994880 individuals were enrolled in this meta-analysis...
September 15, 2016: Panminerva Medica
https://www.readbyqxmd.com/read/27557862/the-use-of-telmisartan-and-the-incidence-of-cancer
#14
Koray Tascilar, Laurent Azoulay, Sophie Dell'Aniello, Dorothee B Bartels, Samy Suissa
BACKGROUND: A meta-analysis reported an 8% increased risk of cancer with the use of angiotensin receptor blockers (ARBs), but subsequent meta-analyses and observational studies did not confirm this risk. However, telmisartan comprised 85% of the data in the original meta-analysis. Thus, the objective of this study was to determine whether the use of telmisartan, compared with other ARBs, is associated with an increased risk of cancer. METHODS: We used the United Kingdom Clinical Practice Research Datalink to assemble a cohort of all patients newly treated with ARBs between 2000 and 2008, and followed until December 2010...
August 24, 2016: American Journal of Hypertension
https://www.readbyqxmd.com/read/27544756/the-association-between-angiotensin-receptor-blocker-usage-and-breast-cancer-characteristics
#15
Hadar Goldvaser, Shulamit Rizel, Daniel Hendler, Victoria Neiman, Daniel Shepshelovich, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
PURPOSE: To evaluate the association between angiotensin receptor blocker (ARB) usage and breast cancer characteristics and outcomes. METHODS: All patients who were treated in our institute for estrogen receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer between April 2005 and March 2012 and whose tumors were sent for Oncotype-DX analysis were included. Medical records were retrospectively reviewed. Data regarding ARB usage were retrieved...
2016: Oncology
https://www.readbyqxmd.com/read/27507083/experimental-and-dft-characterization-antioxidant-and-anticancer-activities-of-a-cu-ii-irbesartan-complex-structure-antihypertensive-activity-relationships-in-cu-ii-sartan-complexes
#16
María S Islas, Alicia Luengo, Carlos A Franca, Mercedes Griera Merino, Laura Calleros, Manuel Rodriguez-Puyol, Luis Lezama, Evelina G Ferrer, Patricia A M Williams
The coordination compound of the antihypertensive ligand irbesartan (irb) with copper(II) (CuIrb) was synthesized and characterized by FTIR, FT-Raman, UV-visible, reflectance and EPR spectroscopies. Experimental evidence allowed the implementation of structural and vibrational studies by theoretical calculations made in the light of the density functional theory (DFT). This compound was designed to induce structural modifications on the ligand. No antioxidant effects were displayed by both compounds, though CuIrb behaved as a weak 1,1-diphenyl-2-picrylhydrazyl radical (DPPH(·)) scavenger (IC50 = 425 μM)...
October 2016: Journal of Biological Inorganic Chemistry: JBIC
https://www.readbyqxmd.com/read/27402638/renin-angiotensin-system-blockade-for-the-risk-of-cancer-and-death
#17
Jian Shen, Yan-Mei Huang, Min Wang, Xue-Zhi Hong, Xin-Nan Song, Xia Zou, Yan-Hong Pan, Wei Ling, Min-Hui Zhu, Xiao-Xi Zhang, Yi Sui, Hai-Lu Zhao
INTRODUCTION: The effects of renin-angiotensin system blockade with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) on cancer remain inconsistent. METHODS: We searched existing databases from 1960 to August 2015, for randomised controlled trials and observational studies (case-control studies and cohort studies) of ARB/ACEI therapy with a minimal one year of follow-up. Outcomes were incidence and mortality of cancer...
July 2016: Journal of the Renin-angiotensin-aldosterone System: JRAAS
https://www.readbyqxmd.com/read/27203227/increased-tumor-response-to-neoadjuvant-therapy-among-rectal-cancer-patients-taking-angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers
#18
Zachary S Morris, Sandeep Saha, William J Magnuson, Brett A Morris, Jenna F Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M Francis, Paul M Harari, Rick Chappell, Stuart Tsuji, Mark A Ritter
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensive medications that have been reported to affect aberrant angiogenesis and the dysregulated inflammatory response. Because of such mechanisms, it was hypothesized that these medications might affect the tumor response to neoadjuvant radiation in patients with rectal cancer. METHODS: One hundred fifteen patients who were treated with neoadjuvant radiation at the University of Wisconsin (UW) between 1999 and 2012 were identified...
August 15, 2016: Cancer
https://www.readbyqxmd.com/read/27158979/the-effect-of-angiotensin-system-inhibitors-angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers-on-cancer-recurrence-and-survival-a-meta-analysis
#19
Taejong Song, Chel Hun Choi, Mi Kyoung Kim, Mi-La Kim, Bo Seong Yun, Seok Ju Seong
To assess the current evidence on the potential benefit of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on cancer recurrence and survival, we comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors screened out duplicates and independently reviewed the eligibility of each study. We included comparative studies comparing the use and nonuse of ACEIs or ARBs in cancer patients. Primary outcomes were disease-free survival (DFS) and overall survival...
January 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/27149494/angiotensin-ii-receptor-blockers-and-cancer-risk-a-meta-analysis-of-randomized-controlled-trials
#20
REVIEW
Yun-Tao Zhao, Peng-Yang Li, Jian-Qiang Zhang, Lei Wang, Zhong Yi
Angiotensin II receptor blockers (ARB) are widely used drugs that are proven to reduce cardiovascular disease events; however, several recent meta-analyses yielded conflicting conclusions regarding the relationship between ARB and cancer incidence, especially when ARB are combined with angiotensin-converting enzyme inhibitors (ACEI).We investigated the risk of cancer associated with ARB at different background ACEI levels.Search of PubMed and EMBASE (1966 to December 17, 2015) without language restriction.Randomized, controlled trials (RCTs) had at least 12 months of follow-up data and reported cancer incidence was included...
May 2016: Medicine (Baltimore)
keyword
keyword
31670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"